Symphogen A/s

Les Laboratoires Servier

Danmarks Tekniske Universitet

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Torben Gjetting

Michael Monrad Grandal

Thomas Bouquin

Gunther Roland Galler

Mikkel Wandahl Pedersen

Michael Kragh

Ivan David Horak

Camilla Fröhlich

Klaus Koefoed

Johan Lantto

Monika Gad

Trine Lindsted

Randi Westh Hansen

Janus Schou Jakobsen

Vikram Kjøller Bhatia

Thomas Lars Andresen

Rasmus Irming Jølck

Jonas Rosager Henriksen

Anne Worsaae

Maria Carlsen Melander

Vikram Kjoller Bhatia

Anton Willer

This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.

Anti-lag-3 antibodies and compositions

This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.

Anti-AXL antibodies and compositions

This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.

Anti-CD73 antibodies and compositions

Anti-LAG-3 antibodies and compositions

This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.

Anti-TIM-3 antibodies and compositions

This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-lactivity, e.g., cancer.

Anti-PD-1 antibodies and compositions

The present application discloses a nanoparticle comprising compounds of the formula A-B-C(-D), wherein A designates an anchoring moiety having self-organizing properties in relation to the nanoparticle; B designates a cleavable linker; C designates an anionic moiety having a net charge of at least &#x2212;2 at pH 6.0; and D, which is optional, designates a polymer moiety which induces long circulating properties of the nanoparticle in mammalian tissue; and wherein the average net charge of the compounds is at least &#x2212;1 at pH 6.0. The application also discloses the individual compounds of the formula A-B-C(-D) as well as a drug delivery system comprising the self-organized nanoparticle having included in the interior thereof one or more pharmaceutically active agents and/or diagnostically relevant species, and a method of treating a cancerous or inflammatory condition in a mammal, involving the administration of the drug delivery system to the mammal.

Charge triggering of self-organized nanoparticles

Growing community of inventors

Jyllinge, Denmark

Torben Gjetting